- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 168145, 8 pages
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
2Departments of Medicine, Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, P.O. Box 1208, New York, NY 10029-6574, USA
3Ludwig Institute of Cancer Research, New York, NY 10065, USA
4Sarcoma and Bone Cancer Treatment Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA
5University of Michigan Cancer Center, Ann Arbor, MI 48109, USA
6Medarex, Inc., Bloomsbury, NJ 08804, USA
7Bristol Myers Squibb Company, Wallingford, CT 06492, USA
8Regeneron, Inc., Tarrytown, NY 10591, USA
Received 12 December 2012; Accepted 27 January 2013
Academic Editor: Akira Kawai
Copyright © 2013 Robert G. Maki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- N. Howlader, A. M. Noone, M. Krapcho et al., Eds., SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute, Bethesda, MD, USA, 2012, http://seer.cancer.gov/csr/1975_2009_pops09/.
- A. J. Spillane, R. A'Hern, I. R. Judson, C. Fisher, and J. M. Thomas, “Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment,” Journal of Clinical Oncology, vol. 18, no. 22, pp. 3794–3803, 2000.
- B. De Leeuw, M. Balemans, D. O. Weghuis et al., “Molecular cloning of the synovial sarcoma-specific translocation (X;18)(p11.2;q11.2) breakpoint,” Human Molecular Genetics, vol. 3, no. 5, pp. 745–749, 1994.
- J. Clark, P. J. Rocques, A. J. Crew et al., “Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma,” Nature Genetics, vol. 7, no. 4, pp. 502–508, 1994.
- E. Dimitriadis, D. Rontogianni, A. Kyriazoglou et al., “Novel SYT-SSX fusion transcript variants in synovial sarcoma,” Cancer Genetics and Cytogenetics, vol. 195, no. 1, pp. 54–58, 2009.
- N. R. dos Santos, D. R. H. de Bruijm, and A. G. van Kessel, “Molecular mechanisms underlying human synovial sarcoma development,” Genes Chromosomes Cancer, vol. 30, pp. 1–14, 2001.
- A. Chrysostomou, “Fusions of the SYT and SSX genes in synovial sarcoma,” Oncogene, vol. 20, no. 40, pp. 5755–5762, 2001.
- J. Przybyl, M. Jurkowska, P. Rutkowski, M. Debiec-Rychter, and J. A. Siedlecki, “Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy,” Sarcoma, vol. 2012, Article ID 249219, 13 pages, 2012.
- H. Al-Hussaini, D. Hogg, M. E. Blackstein, et al., “Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma,” Sarcoma, vol. 2011, Article ID 231789, 7 pages, 2011.
- J. J. Lewis, C. R. Antonescu, D. H. Y. Leung et al., “Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity,” Journal of Clinical Oncology, vol. 18, pp. 2087–2094, 2000.
- F. C. Eilber, M. F. Brennan, F. R. Eilber et al., “Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma,” Annals of Surgery, vol. 246, no. 1, pp. 105–113, 2007.
- J. H. Edmonson, L. M. Ryan, R. H. Blum et al., “Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1269–1275, 1993.
- A. Le Cesne, J. Y. Blay, I. Judson et al., “Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 576–584, 2005.
- K. A. Thornton, “Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma,” Core Evidence, vol. 4, pp. 191–198, 2010.
- M. J. Scanlan, A. J. Simpson, and L. J. Old, “The cancer/testis genes: review, standardization, and commentary,” Cancer Immunity, vol. 4, article 1, 2004.
- N. H. Segal, N. E. Blachere, J. A. Guevara-Patiño et al., “Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics,” Cancer Immunity, vol. 5, article 2, 2005.
- A. A. Jungbluth, C. R. Antonescu, K. J. Busam et al., “Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7,” International Journal of Cancer, vol. 94, no. 2, pp. 252–256, 2001.
- J. P. Lai, P. F. Robbins, M. Raffeld et al., “NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis,” Modern Pathology, vol. 25, no. 6, pp. 854–858, 2012.
- C. R. Antonescu, K. J. Busam, K. Iversen et al., “MAGE antigen expression in monophasic and biphasic synovial sarcoma,” Human Pathology, vol. 33, no. 2, pp. 225–229, 2002.
- E. Stockert, E. Jäger, Y. T. Chen et al., “A survey of the humoral immune response of cancer patients to a panel of human tumor antigens,” Journal of Experimental Medicine, vol. 187, no. 8, pp. 1349–1354, 1998.
- S. Gnjatic, D. Atanackovict, E. Jäger et al., “Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8862–8867, 2003.
- E. Jäger, Y. Nagata, S. Gnjatic et al., “Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4760–4765, 2000.
- F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010.
- J. S. Weber, O. Hamid, S. D. Chasalow et al., “Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma,” Journal of Immunotherapy, vol. 35, no. 1, pp. 89–97, 2012.
- J. Yuan, M. Adamow, B. A. Ginsberg et al., “Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 40, pp. 16723–16728, 2011.
- P. F. Robbins, R. A. Morgan, S. A. Feldman et al., “Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 917–924, 2011.
- S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012.
- R. Simon, “Optimal two-stage designs for phase II clinical trials,” Controlled Clinical Trials, vol. 10, no. 1, pp. 1–10, 1989.
- C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously unreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, pp. 2517–2526, 2011.
- S. A. Rosenberg, “Cell transfer immunotherapy for metastatic solid cancer- what clinicians need to know,” Nature Reviews Clinical Oncology, vol. 8, pp. 577–585, 2011.
- Y. Sato, Y. Nabeta, T. Tsukahara et al., “Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24+ patients with synovial sarcoma,” Journal of Immunology, vol. 169, no. 3, pp. 1611–1618, 2002.
- S. Kawaguchi, T. Wada, K. Ida et al., “Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma,” Journal of Translational Medicine, vol. 3, article 1, 2005.
- T. Tsukahara, S. Kawaguchi, T. Torigoe et al., “Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma,” Cancer Science, vol. 99, no. 2, pp. 368–375, 2008.
- T. Tsukahara, S. Kawaguchi, T. Torigoe et al., “HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor,” Journal of Translational Medicine, vol. 7, article 44, 2009.
- S. Kawaguchi, T. Wada, S. Nagoya et al., “Phase I vaccination trial of SYT-SSX junction peptide and its JLA-*2402 anchor substitute in patients with disseminated synovial sarcoma,” in Proceedings of the Connective Tissue Oncology Society (CTOS '05), 2005, Abstract 364.
- S. Kawaguchi, T. Wada, S. Nagoya et al., “The second vaccination tril of SYT-SSX junction peptide in patients with disseminated synovial sarcoma,” in Proceedings of the Connective Tissue Oncology Society (CTOS '07), 2007, Abstract 817.
- S. Y. Lee, Y. Obata, M. Yoshida et al., “Immunomic analysis of human sarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2651–2656, 2003.
- M. Ayyoub, R. N. Taub, M. L. Keohan et al., “The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma,” Cancer Immunity, vol. 4, article 7, 2004.
- J. D. Wolchok, A. Hoos, S. O'Day et al., “Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria,” Clinical Cancer Research, vol. 15, no. 23, pp. 7412–7420, 2009.
- W. T. van der Graaf, J. Y. Blay, S. P. Chawla, et al., “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 379, no. 9829, pp. 1879–1886, 2012.